Clinical trial

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

NCT01039948

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-12-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2009-12-01Date precision: month

Registry last updated2015-04-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small Cell-Lungunresolved

Lung Neoplasmsunresolved

Lung Cancerunresolved

Respiratory Tract Neoplasmsunresolved

Interventions

AV-299 + gefitinibBIOLOGICAL

GefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

AVEO Pharmaceuticals, Inc.lead sponsor

Mapped research locations

SeoulSouth Korea4 TaipeiTaiwan2 Kuala LumpurMalaysia2 TaichungTaiwan1 SingaporeSingapore1 TainanTaiwan1 BangkokThailand1 TaoyuanTaiwan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01039948 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.